In recent months, the psychedelics space has been ground for increasing collaborations. In some cases it was to advance scientific studies. In others, to offer psychedelic medicine, therapy training and clinical retreats.  

This time, a partnership has been set between Sunstone Therapies, an organization dedicated to the treatment of the psychological effects of cancer, and the Multidisciplinary Association for Psychedelic Studies (MAPS). As per the partnership, Sunstone will commence a novel clinical trial testing the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant PTSD. 

PTSD is rooted in an extremely stressful event and its common symptoms include flashbacks, severe anxiety, uncontrollable thoughts, agitation, social isolation, insomnia and emotional detachment. 

In the US alone, more than 8% of people will experience PTSD sometime in their …

Full story available on Benzinga.com